全文获取类型
收费全文 | 3482篇 |
免费 | 264篇 |
国内免费 | 145篇 |
专业分类
耳鼻咽喉 | 192篇 |
儿科学 | 30篇 |
妇产科学 | 18篇 |
基础医学 | 219篇 |
口腔科学 | 61篇 |
临床医学 | 251篇 |
内科学 | 447篇 |
皮肤病学 | 74篇 |
神经病学 | 95篇 |
特种医学 | 142篇 |
外科学 | 180篇 |
综合类 | 364篇 |
预防医学 | 390篇 |
眼科学 | 18篇 |
药学 | 941篇 |
1篇 | |
中国医学 | 390篇 |
肿瘤学 | 78篇 |
出版年
2024年 | 6篇 |
2023年 | 64篇 |
2022年 | 78篇 |
2021年 | 200篇 |
2020年 | 165篇 |
2019年 | 136篇 |
2018年 | 148篇 |
2017年 | 126篇 |
2016年 | 128篇 |
2015年 | 137篇 |
2014年 | 230篇 |
2013年 | 285篇 |
2012年 | 194篇 |
2011年 | 197篇 |
2010年 | 165篇 |
2009年 | 149篇 |
2008年 | 159篇 |
2007年 | 146篇 |
2006年 | 140篇 |
2005年 | 122篇 |
2004年 | 98篇 |
2003年 | 69篇 |
2002年 | 79篇 |
2001年 | 85篇 |
2000年 | 71篇 |
1999年 | 51篇 |
1998年 | 61篇 |
1997年 | 42篇 |
1996年 | 42篇 |
1995年 | 37篇 |
1994年 | 31篇 |
1993年 | 31篇 |
1992年 | 34篇 |
1991年 | 21篇 |
1990年 | 20篇 |
1989年 | 13篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 11篇 |
1985年 | 19篇 |
1984年 | 17篇 |
1983年 | 7篇 |
1982年 | 14篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1979年 | 8篇 |
1978年 | 3篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1973年 | 2篇 |
排序方式: 共有3891条查询结果,搜索用时 31 毫秒
1.
ABSTRACT
Introduction
Acne is a chronic, inflammatory, and immune mediated disease of pilosebaceous unit, highly prevalent in adolescents. It involves face, trunk, and back; may leave scars and affect quality of life. Early, effective, and safe treatment is the key for disease resolution. Oral isotretinoin is the unique treatment for cure or prolonged remission for moderate and severe acne, preventing psychosocial impact and scars. It inhibits sebaceous glands activity and has anti-inflammatory and immunoregulatory properties. 相似文献2.
《European journal of surgical oncology》2020,46(1):155-159
IntroductionElectrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC) has shown superior penetration depth and tissue uptake compared to standard PIPAC. We investigated the feasibility and objective tumor response to ePIPAC with 1 min of precipitation in patients with peritoneal metastasis (PM).Materials and methodsPatients with PM from various abdominal cancers were included in an amendment to the ongoing prospective PIPAC-OPC2 trial. Colorectal and appendiceal PM were treated with oxaliplatin, patients with PM from other primaries were treated with a combination of cisplatin and doxorubicin. Three ePIPAC procedures were planned in each patient including repeated peritoneal biopsies for response evaluation. After emission to the peritoneal cavity, the aerosolized chemotherapeutics were precipitated for 1 min followed by immediate exsufflation and abdominal closure. Histological regression from the first to the third ePIPAC was evaluated according to the Peritoneal Regression Grading Score (PRGS) and compared to data from the PIPAC-OPC1 trial. Complications and toxicities were recorded according to Dindo-Clavien and CTCAE.ResultsSixty-five ePIPAC procedures were performed in 33 patients (median 2, range 1–6). Ten patients were eligible for response evaluation based on biopsies from the first and third ePIPAC procedure. Four patients had disease progression, four patients had regressive disease, and two patients had stable disease according to PRGS. No life threatening adverse reactions and no mortality was observed following ePIPAC.ConclusionOne minute ePIPAC was feasible and safe, but the histological tumor response was insufficient compared to standard PIPAC directed therapy with 30 min passive diffusion time. 相似文献
3.
Ignacio Mejía‐Calvo Leonardo E. Lpez‐Jurez Said Vzquez‐Leyva Carlos A. Lpez‐Morales Daniel Montoya‐Escutia Pamela G. Merlos Rivera Jos Enrique Herbert‐Pucheta Luis Gerardo Zepeda‐Vallejo Marco Velasco‐Velzquez Lenin Pavn Sonia M. Prez‐Tapia Emilio Medina‐Rivero 《Journal of Cosmetic Dermatology》2021,20(1):150-158
4.
Weifeng Tang Helena Engman Yali Zhu Brian Dayton David W. Boulton 《Clinical therapeutics》2019,41(8):1545-1563
PurposeFixed-combination drug products (FCDPs) for patients with type 2 diabetes mellitus (T2DM) may show efficacy comparable to their individual components (ICs) while improving adherence to treatment. This study evaluated the bioequivalence and safety of 2 dapagliflozin/saxagliptin/metformin extended-release (XR) FCDPs relative to their ICs: saxagliptin and dapagliflozin/metformin XR.MethodsThis randomized, open-label, single-dose, single-center crossover study was conducted in 84 healthy subjects aged 18–55 years. The primary objective was to evaluate the fed-state bioequivalence of a dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP and a dapagliflozin 10-mg/saxagliptin 5-mg/metformin 1000-mg XR FCDP relative to the ICs. Secondary objectives included the evaluation of the effect of food on the pharmacokinetic (PK) parameters of saxagliptin, dapagliflozin, and metformin in both FCDPs and characterization of the PK parameters of the active metabolite of saxagliptin, 5-hydroxy saxagliptin, in healthy subjects. PK parameters (AUC0–∞, AUC0–t, and Cmax) were used to assess the bioequivalence of the 2 FCDPs with their ICs. The Cmax and AUC0–t of the study drugs were compared between female and male subjects to assess sex differences in exposure. Safety and tolerability of both FCDPs and ICs were also assessed with adverse events, vital signs (systolic and diastolic blood pressures and pulse rate), 12-lead ECG, physical examinations, and laboratory assessments.FindingsBoth dapagliflozin/saxagliptin/metformin XR FCDPs were bioequivalent to their ICs. For the dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP, the 90% CI for the geometric mean ratio of dapagliflozin Cmax was slightly above the 80%–125% bioequivalence limit, which is unlikely to be clinically relevant. Food delayed the absorption of the study drugs in both FCDPs, which is unlikely to have a clinically relevant impact on efficacy. In both cohorts, exposure was higher in female subjects compared with male subjects, potentially due to the lower body weight of the female subjects. The safety profile and tolerability of the FCDPs were similar to those of their ICs, and no deaths or serious adverse events were reported.ImplicationsThese data support the use of the dapagliflozin/saxagliptin/metformin XR FCDP in patients with T2DM. ClinicalTrials.gov identifier: NCT03169959. 相似文献
5.
《Journal of endodontics》2019,45(10):1209-1218
IntroductionThe aims of this in vivo cone-beam computed tomographic (CBCT) study were to evaluate the prevalence, characteristics, and correlations between the fused rooted maxillary first and second molars as well as their consequent merged and C-shaped canals in a Saudi Arabian population.MethodsCBCT imaging of 726 maxillary first and second molars from 208 subjects of Saudi origin were evaluated in the present study. The prevalence of fused rooted maxillary molars, merged canals, C-shaped configurations, and correlations between the presence of fused rooted teeth between first and second molars were examined as the primary outcome. Differences by sex, location in the jaw, and bilateral symmetry (similarity between right- and left-side teeth in the same patient) were evaluated as the secondary outcome. The Z test was used for differences in the independent proportions, the chi-square test was used for differences between sex and locations, and the Cohen kappa test was used for bilateral symmetry. The kappa test was also used for intrarater reliability. A value of P < .05 was considered significant.ResultsThe prevalence of fused rooted maxillary first and second molars was 7% and 21%, respectively. Within fused rooted teeth, the presence of merged canals was 8.3% and 32.1%, whereas the prevalence of C-shaped canals was 8.3% and 5.1% in first and second maxillary molars, respectively. Among 57 subjects who had fused rooted maxillary molars, 19.3% showed a correlation between first and second molars. In fused rooted maxillary molars, 3.8% first molars and 13% second molars were bilaterally symmetrical. There were no statistically significant differences between sexes and right- and left-sided fused rooted maxillary molars, merged canals, or C-shaped canals.ConclusionsMaxillary second molars presented more complex external and internal morphology compared with maxillary first molars, with an overall prevalence of 14% of fused rooted maxillary molars and 3.7% merged and 0.8% C-shaped canal configurations for all maxillary molars. The clinician should be aware of such challenges, and for a better treatment outcome, the use of CBCT imaging (small field of view) and an operative dental microscope can be considered when a preoperative periapical radiograph shows signs of fused rooted maxillary molars. 相似文献
6.
目的 针对中医药大数据平台传统的加密方案效率不高的问题,提出一种高效的基于属性的内积加密的数据脱敏算法。方法 Hash(哈希)算法是应用广泛的高效的数据加密方法,但传统的哈希算法基于单一的控制策略,效率不高。本文提出一种基于属性的内积加密的数据脱敏算法,把批量的敏感数据分割为不同长度数据颗粒度,与特定密文的哈希进行内积处理。结果 在面对中医药大数据平台的海量数据加密的场景,与传统的哈希加密算法相比,本文提供的加密算法具有很好的性能。结论 为了保障个人隐私数据不被泄露,中医药大数据平台中的个人医疗数据需要加密脱敏后,才能进行分析处理或对外发布。本文提出的算法具备灵活的数据颗粒度、策略和高效的性能表现,适用于海量的中医药数据脱敏。 相似文献
7.
目的 制备pH敏感释药的As2O3脂质体,并进行体外评价。方法 采用薄膜分散法制备含钙离子脂质体,然后用离子沉淀法孵育制备钙砷复合物脂质体(CaAs-LP)。测定CaAs-LP的粒径、Zeta电位及多分散系数(PDI);透射电子显微镜观察脂质体的形态;电感耦合等离子体发射光谱仪测定纳米药物的载药量与包封率;透析袋法考察其体外释药特性。噻唑蓝(MTT)法考察未载药脂质体及CaAs-LP对人源性乳腺癌MCF-7细胞、人源性脑胶质瘤U87细胞和人源性肝癌HepG2细胞的毒性;共聚焦显微镜考察U87细胞对CaAs-LP的摄取效率。结果 制备的CaAs-LP呈规整类球型,粒径约为(117.16±1.94)nm,包封率和载药量分别为(74.31±2.11)%、(8.31±0.13)%。体外释放研究表明,CaAs-LP具有明显的缓释以及pH响应释药特征。未载药的脂质体在MCF-7、U87、HepG2和L02细胞中的生物相容性良好;CaAs-LP抑制肿瘤细胞生长的作用较原药有所上升,半数抑制浓度(IC50)值分别为11.91、4.90、19.41、27.59 μmol/L。细胞摄取研究表明肝癌细胞对脂质体具有良好的摄取。结论 CaAs-LP具备显著的缓释以及pH响应释药的特性,在肿瘤治疗方面具有较好的应用前景。 相似文献
8.
9.
10.
《Vaccine》2020,38(30):4717-4731
This is a Brighton Collaboration case definition of the term “Sensorineural Hearing Loss” to be utilized in the evaluation of adverse events following immunization. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for Lassa Fever and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and define levels of diagnostic certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network. 相似文献